You are here: Industry Insights > Celgene

News List

Sun Pharma announces settlement of patent litigation for generic Revlimid in the US expresspharma
June 23, 2021
Sun Pharma, along with one of its wholly-owned subsidiaries today announced that they have reached an agreement with Celgene Corporation (Celgene), a wholly-owned subsidiary of Bristol Myers Squibb, to resolve the patent litigation regarding ...
Bristol Myers faces $6.4bn lawsuit over cancer drug delay pharmaceutical-technology
June 07, 2021
UMB Bank, a trustee for Celgene’s former shareholders, has filed a lawsuit against Bristol Myers Squibb (BMS) for allegedly delaying the development and manufacturing of cancer drug lisocabtagene maraleucel (Liso-cel) to avoid contingent value right (CVR)
Cipla settles patent litigation of Revlimid (lenalidomide) capsules with Celgene expresspharma
December 14, 2020
Celgene has agreed to provide Cipla with a license to Celgene’s patents required to manufacture and sell certain volume-limited amounts of generic lenalidomide in the US beginning on a confidential date that is some time after March 2022.
NICE turns down Celgene's Revlimid as multiple myeloma maintenance treatment pharmatimes
September 23, 2020
The National Institute for Heath and Care Excellence (NICE) has turned down NHS funding of Celgene's Revlimid (lenalidomide) as maintenance treatment after an autologous stem cell transplant for newly diagnosed multiple myeloma in adults.
Dr Reddy’s announces settlement of Revlimid capsules patent litigation with Celgene in US expresspharma
September 18, 2020
Celgene has agreed to provide Dr Reddy’s with a license to sell volume-limited amounts of generic lenalidomide capsules in the US beginning on a confidential date after March 2022 subject to regulatory approval.
USFDA extends review of Bristol Myers’ cancer therapy acquired in Celgene deal expresspharma
May 07, 2020
The company said it had submitted additional information on the therapy known as liso-cel, which was considered a major amendment to the marketing application by the agency.
Amid a political firestorm over pharma's pricing, net prices actually fell last quarter fiercepharma
September 26, 2019
Celgene, Biogen, Novartis, Allergan and Bausch Health added most to net prices, while lower net prices at Gilead Sciences, Johnson & Johnson, Novo Nordisk, GlaxoSmithKline and Sanofi dragged down the overall total.
Amgen to acquire Otezla® for $13.4 billion in cash worldpharmanews
August 27, 2019
Amgen announced today that it has entered into an agreement with Celgene Corporation in connection with its previously announced merger with Bristol-Myers Squibb Company to acquire...
Amgen Acquires Rights to Celgene’s Otezla contractpharma
August 27, 2019
Expands inflammation franchise with oral, non-biologic treatment for psoriasis and psoriatic arthritis.
Celgene’s bone marrow cancer drug Inrebic secures FDA approval pharmaceutical-technology
August 20, 2019
Celgene has received the US Food and Drug Administration (FDA) approval for the use of its Inrebic (fedratinib) drug to treat adults with myelofibrosis, a rare bone marrow cancer.

Previous page 1 2 3 4 5 6 7 8 9 10 11 Next page